$MTEM
Molecular Templates, Inc.

2017 Q2 Form 10-Q Financial Statement

#000156459017014516 Filed on July 31, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q4 2016 Q2
Revenue $42.00K $0.00 $1.530M
YoY Change -97.25% -100.0% -58.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.450M $1.950M -$510.0K
YoY Change -580.39% -13.33% -120.56%
% of Gross Profit
Research & Development $1.240M $3.010M -$1.100M
YoY Change -212.73% -73.53% -110.85%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $120.0K
YoY Change -83.33% -92.0% -53.85%
% of Gross Profit
Operating Expenses $3.690M $4.960M $5.908M
YoY Change -37.54% -63.58% -53.19%
Operating Profit
YoY Change
Interest Expense $422.0K $40.00K $40.00K
YoY Change 955.0% 33.33% 2.56%
% of Operating Profit
Other Income/Expense, Net $1.250M -$996.0K
YoY Change -92.83% -267.11%
Pretax Income -$4.060M -$3.680M $2.580M
YoY Change -257.36% -105.28% -131.05%
Income Tax
% Of Pretax Income
Net Earnings -$4.060M -$3.682M -$6.864M
YoY Change -40.85% -105.28% -17.36%
Net Earnings / Revenue -9666.67% -448.63%
Basic Earnings Per Share -$0.05 -$0.10
Diluted Earnings Per Share -$19.33M -$0.05 -$0.10
COMMON SHARES
Basic Shares Outstanding 71.56M 71.51M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q4 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.80M $1.700M $33.60M
YoY Change -50.0% -96.51% -49.85%
Cash & Equivalents $4.608M $1.716M $12.40M
Short-Term Investments $300.0K
Other Short-Term Assets $100.0K $7.000K $1.300M
YoY Change -92.31% -99.73% -13.33%
Inventory
Prepaid Expenses $120.0K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $20.90M $1.843M $35.80M
YoY Change -41.62% -96.53% -50.42%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $334.0K $200.0K
YoY Change -100.0% 0.3% -52.83%
Goodwill $0.00
YoY Change
Intangibles $921.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $200.0K
YoY Change -100.0% -84.18%
Total Long-Term Assets -$39.00K $22.44M $400.0K
YoY Change -109.75% 4396.99% -75.82%
TOTAL ASSETS
Total Short-Term Assets $20.90M $1.843M $35.80M
Total Long-Term Assets -$39.00K $22.44M $400.0K
Total Assets $20.86M $24.28M $36.20M
YoY Change -42.37% -54.75% -50.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $319.0K $822.0K $3.100M
YoY Change -89.71% 13.38% 388.19%
Accrued Expenses $2.200M $888.0K $2.700M
YoY Change -18.52% -72.84% 10.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $7.300M $0.00
YoY Change
Long-Term Debt Due $2.400M
YoY Change
Total Short-Term Liabilities $2.500M $13.77M $5.800M
YoY Change -56.9% 27.12% -77.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $3.165M $0.00
YoY Change
Other Long-Term Liabilities $1.500M $53.00K $2.600M
YoY Change -42.31% -97.35% -96.51%
Total Long-Term Liabilities $1.500M $3.218M $2.600M
YoY Change -42.31% 60.9% -96.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.500M $13.77M $5.800M
Total Long-Term Liabilities $1.500M $3.218M $2.600M
Total Liabilities $4.000M $17.03M $8.400M
YoY Change -52.38% 32.82% -91.61%
SHAREHOLDERS EQUITY
Retained Earnings -$40.37M
YoY Change -87.74%
Common Stock $568.0K
YoY Change -99.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.90M -$39.81M $27.80M
YoY Change
Total Liabilities & Shareholders Equity $20.90M $3.098M $36.20M
YoY Change -42.27% -94.23% -50.98%

Cashflow Statement

Concept 2017 Q2 2016 Q4 2016 Q2
OPERATING ACTIVITIES
Net Income -$4.060M -$3.682M -$6.864M
YoY Change -40.85% -105.28% -17.36%
Depreciation, Depletion And Amortization $20.00K $20.00K $120.0K
YoY Change -83.33% -92.0% -53.85%
Cash From Operating Activities $360.0K -$830.0K -$4.370M
YoY Change -108.24% -89.04% -72.46%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$70.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$70.00K -$220.0K $5.560M
YoY Change -101.26% -106.43% 3.35%
Cash From Investing Activities -$80.00K -$290.0K $5.560M
YoY Change -101.44% -108.48% 3.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.390M 1.210M 0.000
YoY Change 3933.33%
NET CHANGE
Cash From Operating Activities 360.0K -830.0K -4.370M
Cash From Investing Activities -80.00K -290.0K 5.560M
Cash From Financing Activities 1.390M 1.210M 0.000
Net Change In Cash 1.670M 90.00K 1.190M
YoY Change 40.34% -102.18% -111.33%
FREE CASH FLOW
Cash From Operating Activities $360.0K -$830.0K -$4.370M
Capital Expenditures -$10.00K -$70.00K
Free Cash Flow $370.0K -$760.0K
YoY Change -89.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Assets
Assets
20861000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
319000
CY2017Q2 thld Collaboration Payable
CollaborationPayable
0
CY2017Q2 thld Notes Receivable Current
NotesReceivableCurrent
4000000
CY2016Q4 thld Notes Receivable Current
NotesReceivableCurrent
0
CY2016Q4 us-gaap Assets
Assets
24283000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
822000
CY2016Q4 thld Collaboration Payable
CollaborationPayable
129000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
21000
thld Increase Decrease In Receivables Or Payables From Collaboration Partners
IncreaseDecreaseInReceivablesOrPayablesFromCollaborationPartners
129000
us-gaap Share Based Compensation
ShareBasedCompensation
919000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
25000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
249000
thld Increase Decrease In Receivables Or Payables From Collaboration Partners
IncreaseDecreaseInReceivablesOrPayablesFromCollaborationPartners
-970000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-530000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-503000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-531000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1027000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
36000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-14999000
thld Issuance Of Promissory Note To Molecular Templates
IssuanceOfPromissoryNoteToMolecularTemplates
4000000
thld Issuance Of Promissory Note To Molecular Templates
IssuanceOfPromissoryNoteToMolecularTemplates
0
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
299000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
13454000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
61000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
13006000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
31192000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
8807000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17799000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5917000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2813000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9589000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12402000
CY2017Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
29000
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
414000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
802000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
919000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1645000
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10941745
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
209485
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10732260
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10689426
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8640234
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.37
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.03
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.04
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M28D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y10M21D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y0M26D
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2730
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2730
CY2017Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2730
us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
0
CY2017Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
14402000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
23217000
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
299000
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
299000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
13002000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
13000000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P1M
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
0
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
8300000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000

Files In Submission

Name View Source Status
0001564590-17-014516-index-headers.html Edgar Link pending
0001564590-17-014516-index.html Edgar Link pending
0001564590-17-014516.txt Edgar Link pending
0001564590-17-014516-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20170630.htm Edgar Link pending
thld-20170630.xml Edgar Link completed
thld-20170630.xsd Edgar Link pending
thld-20170630_cal.xml Edgar Link unprocessable
thld-20170630_def.xml Edgar Link unprocessable
thld-20170630_lab.xml Edgar Link unprocessable
thld-20170630_pre.xml Edgar Link unprocessable
thld-ex311_9.htm Edgar Link pending
thld-ex312_8.htm Edgar Link pending
thld-ex321_7.htm Edgar Link pending
thld-ex322_6.htm Edgar Link pending